Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Free Cash Flow (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Free Cash Flow data on record, last reported at -$19.7 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 69.46% year-over-year to -$19.7 million; the TTM value through Sep 2025 reached -$62.8 million, down 65.05%, while the annual FY2024 figure was -$41.2 million, 52.97% down from the prior year.
  • Free Cash Flow reached -$19.7 million in Q3 2025 per CAPR's latest filing, up from -$20.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $23.5 million in Q1 2022 and bottomed at -$20.4 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$6.9 million, with a median of -$7.3 million recorded in 2025.
  • Peak YoY movement for Free Cash Flow: soared 797.47% in 2022, then plummeted 290.49% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$6.0 million in 2021, then dropped by 26.68% to -$7.6 million in 2022, then plummeted by 59.99% to -$12.2 million in 2023, then dropped by 25.78% to -$15.3 million in 2024, then decreased by 29.18% to -$19.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$19.7 million in Q3 2025, -$20.4 million in Q2 2025, and -$7.3 million in Q1 2025.